Theranostics Market to Surge to US$ 7.56 Billion by 2033, Fueled by a 15.4% CAGR | GE Healthcare, Jubilant Pharmova Limited (Jubilant Pharma Limited), Theragnostics Ltd.

The global theranostics market reached US$ 2.13 billion in 2023, with a rise to US$ 2.40 billion in 2024, and is expected to reach US$ 7.56 billion by 2033, growing at a CAGR of 15.4% during the forecast period 2025-2033.

Key Points:

2024 Market Size: US$ 2.40 Billion

2033 Projected Market Size: US$ 7.56 Billion

CAGR (2025-2033): 15.4%

North America: Largest market in 2024

Asia Pacific: Fastest-growing market

The Theranostics Market integrates therapy and diagnostics to personalize treatment, primarily in oncology. Growth is driven by demand for precision medicine, biomarker-based therapies, and targeted imaging. Hospitals, research institutes, and diagnostic centers are major users. Innovations focus on radiopharmaceuticals and molecular imaging. Regulatory support for personalized treatment boosts adoption. Rising cancer incidence and technological progress accelerate market expansion.

📌 Download Sample Report to Identify Emerging Deals & Opportunities in the Theranostics Market Landscape:- https://datamintelligence.com/download-sample/theranostics-market?Ranjith

☛ Theranostics Market Recent Developments 2025:

United States: Recent Industry Developments

✅ In September 2025, Novartis AG (U.S.) announced FDA approval of Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) for earlier-line treatment of metastatic castration-resistant prostate cancer (mCRPC). The approval expands access to radioligand therapy in combination with androgen receptor inhibitors.

✅ In August 2025, GE HealthCare launched its Precision Molecular Imaging Platform integrating PET/CT scanners with AI-based lesion quantification to support personalized theranostic workflows for oncology patients.

✅ In July 2025, Bayer Pharmaceuticals initiated a Phase 2 trial of its novel alpha-emitter radiopharmaceutical (Ra-224 compound) for treating neuroendocrine tumors, focusing on enhanced tumor selectivity and reduced toxicity.

✅ In May 2025, Siemens Healthineers expanded its partnership with Theranostics Inc. to develop automated radiopharmaceutical manufacturing modules, streamlining production of Ga-68 and Lu-177-based agents for clinical use.

Japan: Recent Industry Developments

✅ In September 2025, Fujifilm Toyama Chemical Co., Ltd. launched a radioisotope imaging research program in collaboration with RIKEN Institute to develop next-generation PET tracers for early cancer detection and targeted radiotherapy.

✅ In August 2025, Takeda Pharmaceutical Co., Ltd. partnered with National Cancer Center Japan to study the efficacy of radiotheranostic agents targeting HER2-positive tumors, integrating diagnostics with localized radionuclide delivery.

✅ In July 2025, Shimadzu Corporation introduced its automated radiopharmaceutical synthesizer designed for rapid on-site preparation of Ga-68 and F-18 tracers, enhancing clinical availability in nuclear medicine departments.

✅ In June 2025, Sumitomo Heavy Industries upgraded its cyclotron systems to support increased production of short-lived isotopes for use in theranostic imaging and therapy applications.

☛ Theranostics Market Competitive Landscape:

GE Healthcare, Jubilant Pharmova Limited (Jubilant Pharma Limited), Theragnostics Ltd., NuView Life Sciences, Lantheus Holdings, Inc., CapVest Limited (Curium Pharma), Clarity Pharmaceuticals, Cardinal Health, LLC, Advanced Accelerator Applications, and ITM Isotopen Technologien München AG among others.

Research Methodology

We follow a hybrid research approach, combining qualitative insights with rigorous quantitative analysis to deliver reliable and comprehensive market intelligence. Our process begins with extensive secondary research, drawing on trusted industry reports, proprietary databases, and credible market sources. This is then reinforced through targeted primary research, including structured surveys and in-depth interviews with industry leaders, subject matter experts, and key market participants.

📌 Request a Customized Market Report - Tailored insights to match your business goals: https://datamintelligence.com/customize/theranostics-market?Ranjith

☛ Segments Covered in the Theranostics Market:

By Application: Oncology, Neurological Disorder, Cardiovascular Disease and Others.

By Radioisotopes: Technetium-99, Gallium-68, Lutetium (Lu) 177, Iodine-131, Zirconium-89 , Y-90 and Others.

By End User: Hospitals, Cancer Research Institutes, Diagnostic Centers and Others.

☛ This Report Includes:

✔ Comprehensive go-to-market strategies with actionable insights.

✔ Unbiased evaluation of overall market performance.

✔ Deep-dive analysis into development trends, competitive landscape, supply-demand dynamics, YoY growth, benchmarking, vendor mapping, market access, and overall progress.

✔ Tailored regional and country-level reports with detailed localized analysis available on request.

✔ Identification of niche segments and high-growth regions presenting strong opportunities.

✔ Accurate regional forecasts using both top-down and bottom-up approaches.

📌 Get Corporate Access to Live Theranostics Industry Intelligence Database: https://www.datamintelligence.com/buy-now-page?report=theranostics-market?Ranjith

☛ Regional Analysis for Theranostics Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.